4
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Semantics and the Chemotherapy of Hodgkin's Disease—Resistance is Not Relapse: Alternative Chemotherapy Lacks Effectiveness for Disease Not Totally Responsive to Initial MOPP Treatment

&
Pages 237-239 | Published online: 11 Jun 2009

References

  • Fisher R I, DeVita V T, Hubbard S P, et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90: 761–763
  • Vinciguerra V P, Coleman M, Degnan R J. Combination chemotherapy for MOPP-resistant Hodgkin's disease (BVDS) (Abstract). Clin Res 1975; 23: 284
  • Vinciguerra V P, Coleman M, Jarowski C I, et al. A new combination chemotherapy for resistant Hodgkin's disease. J Am Med Assoc 1977; 237: 33–35
  • Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982; 96: 139–143
  • Straus D J, Passe S, Koziner B, et al. Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: An analysis of prognostic factors in two chemotherapy trials and the literature. Cancer Treat Rep 1981; 65: 207–211
  • Sutcliff S B, Wrigley P FM, Stansfeld A G, Malpas J S. Adriamy-cin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine, and prednisone (MVPP). Cancer Chemother Pharmacol 1979; 2: 209–213
  • Clamon G H, Corder M P. ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy. Cancer Treat Rep 1978; 62: 363–367
  • Harker W G, Kushlan P, Rosenberg S A. Combination chemotherapy for advanced Hodgkin;s disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 1984; 101: 440–446
  • Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 1983; 1: 432–439
  • Goldman J M, Dawson A A. Combination therapy for advanced resistant Hodgkin's disease. Lancet 1975; 2: 1224–1227
  • Gold J M, Dawson A A. Chemotherapy for advanced resistant Hodgkin's disease (Letter). Lancet 1981; 2: 252
  • Einhorn L H, Williams S D, Stevens E E, et al. Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. Cancer 1983; 51: 1348–1352
  • Lokich J J, Frei E, Jaffe N, Tullis J. New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease. Cancer 1976; 38: 667–671
  • Stutzman L, Glidewell O. Multiple chemotherapeutic agents for Hodgkin's disease. J Am Med Assoc 1973; 225: 1202–1211
  • Kuentz M, Reyes F, Brun B, et al. Early responses to chemotherapy as a prognostic factor in Hodgkin's disease. Cancer 1983; 52: 780–785
  • Coleman M. Chemotherapy for large-cell lymphoma: optimism and caution (Edit). Ann Intern Med 1985; 103: 140–142
  • Goldie J H, Cddman A T, Gudauskas G A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
  • Coleman M, Vinciguerra V P, Rafla S. Combination chemoim-munotherapy in advanced recurrent Hodgkin's disease: A randomized study of the Cancer and Leukemia Group B (Abstr). Proc Am Soc Cancer Res: Am Soc Clin Oncol 1979; 20: 428
  • Santoro A, Bonadonna G, Bonfante V, Valgussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306: 770–775
  • Vinciguerra V P, Propert K J, Coleman M, et al. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy: A prospective randomized study by the Cancer and Leukemia Group B. J Clin Oncol 1986; 4: 838–846

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.